(OAKVILLE, Ontario) June 11, 2026 – FORUS Therapeutics Inc (“FORUS”) is pleased to announce that it has been acquired by PharmaEssentia Corporation, a global biopharmaceutical company focused on developing innovative therapies for hematology, oncology, and immunology.
This milestone builds on the successful collaboration established between FORUS and PharmaEssentia through the Canadian commercialization partnership for ropeginterferon alfa-2b, an investigational treatment currently under review by Health Canada for patients living with polycythemia vera (PV).
As part of PharmaEssentia, FORUS will continue to leverage its established expertise in the Canadian hematology and oncology environment while benefiting from expanded global resources and capabilities. The integration strengthens the combined organization’s ability to support regulatory, medical, market access, and commercial activities across Canada.
FORUS has built a strong reputation for bringing innovative therapies to Canadian patients and we look forward to continuing to do so alongside the Canadian healthcare community. The acquisition recognizes the value of the existing foundational partnership with Karyopharm and looks to create new opportunities to further support patients living with myeloproliferative neoplasms (MPNs) and other hematologic conditions.
“Our team is excited to become part of PharmaEssentia and to continue advancing our shared commitment to the Canadian hematology community,” said Kevin Leshuk, Chief Executive Officer of FORUS Therapeutics. “Together, we are well positioned to build on our existing capabilities and support access to innovative treatment options for patients across Canada.”
The FORUS team will continue its work with existing healthcare professionals, patient communities, and partners while supporting the advancement of PharmaEssentia’s growing hematology and oncology portfolio in Canada.
This transaction marks an important step in expanding the organization’s long-term presence in Canada and reinforces its commitment to improving outcomes for patients through scientific innovation and collaboration.
About PharmaEssentia
PharmaEssentia (TWSE: 6446), headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.
For more information about PharmaEssentia USA, visit the website, LinkedIn or Twitter.
About FORUS Therapeutics
FORUS Therapeutics is a Canadian specialty pharmaceutical company focused on bringing innovative therapies to patients in hematology, oncology, and other areas of significant unmet medical need. The company combines deep therapeutic expertise with strong regulatory, medical, and commercial capabilities to support the successful introduction of novel treatments in Canada.
For Further Information and Media Inquiries: Kevin Leshuk, General Manager, FORUS Therapeutics Inc. (media@forustherapeutics.com)
References
PharmaEssentia and BESREMi are trademarks or registered trademarks of PharmaEssentia Corporation and are used by FORUS under license.
Read on LinkedIn
Read more on Business Wire